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ASSESSING THE IMPACT OF TUMOR EVOLUTION ON ONCOLOGY DRUG
DEVELOPMENT AND COMMERCIALIZATION
By Joseph P. Sterk
Submitted to the Harvard-MIT Division of Health Sciences and Technology in partial
fulfillment of the requirements for the degree of Master of Science in Health Sciences and
Technology
This thesis investigates the commercial viability of developing and commercializing targeted
oncology drugs directed at a specific tumor mutation instead of all forms and mutations of a
single target. While oncologic drugs targeted to aberrant or overexpressed pro-proliferative
proteins have revolutionized cancer treatment, tumors treated for long periods may mutate over
time, gain resistance to these drugs and proliferate rapidly again. I hypothesize that drugs
developed to inhibit specific resistant tumor genotypes can be commercially viable from a
pharmaceutical manufacturer's perspective.
To assess this hypothesis empirically, I construct a patient flow model in order to quantify the
treatment of CML, a relatively rare and indolent hematological malignancy with extensive
clinical data available and well-delineated disease phases and response criteria. To represent the
rate of diagnosis, patients are "added" to the model every month, and thereafter there is a
probability that a patient may either 1) become sufficiently intolerant to his drug in order to
discontinue treatment, 2) fail to respond to treatment but remain in the same disease phase, 3) fail
to respond to treatment and progress to the next phase of disease, or 4) adequately respond to
treatment and stay on the same drug in the same phase. Patients that fail to respond (categories 2
and 3 above) have a chance of manifesting a resistance mutation that is adequately controlled by
a hypothetical drug (in addition to their current treatment) but is otherwise untreatable. The aim
of this analysis is to track the number of patients that accrue the chosen resistance mutation and
thus would be good candidates to receive the hypothetical drug. Patient treatment rates are
converted to sales figures, and are weighed against clinical development costs, timelines, and
probabilities to determine the net present value (NPV) of a project to develop the hypothetical
drug. In addition, parameters are varied in order to conduct a sensitivity analysis and determine
the "boundary conditions" that make a drug profitable or unprofitable.
To supplement the model results and confirm the model dynamics, I interviewed investment
analysts, clinical oncology thoughtleaders, academic cancer researchers and
clinical, commercial and regulatory personnel from drug manufacturers to gauge their opinions
on the CML market and the hurdles particular to developing drugs aimed at resistant genotypes.
The conclusion I reach from this analysis is that development of a specific mutation-directed
therapy for resistant CML is unlikely to be profitable. Given the significantly smaller patient
population, favorable conditions in pricing and clinical development would be required to make
the hypothetical candidate even marginally profitable.
Thesis Supervisors: Prof. Ernst Berndt - Louis E. Seely Professor in Applied Economics
Mark Trusheim - Visiting Scientist
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Introduction
Cancer therapy has evolved from the use of purely cytotoxic chemotherapy to a combination
approach frequently combining one or more of chemotherapy and targeted inhibitors of cell
proliferation, signal transduction and angiogenesis. The utility of chemotherapy was discovered
during World War II, when an explosion in an Italian harbor exposed American sailors to
nitrogen mustard (still used as the alkylating agent mechlorethamine) and induced profound
myelosuppression'. Consequently, nitrogen mustard was first medically administered to a non-
Hodgkin's lymphoma patient at Yale Medical Center and induced a partial tumor response.
The latter half of the 20*' century saw the rational design of cytotoxic agents (including the
antifolates) and use of natural products (including the vinca alkaloids and taxanes), as well as the
introduction of immunotherapy. While often effective, these agents often failed due to substantial
off-target effects. More recently, advances in cancer biology have led to the development of
drugs that specifically target cancer cells. Many require the use of clinical biomarker testing of
either patient or tumor in order to achieve a meaningful therapeutic benefit, an approach termed
"stratified medicine."
Cancer treatment fulfills the three necessary conditions for stratified medicine laid out by
Trusheim et al: a differential biological mechanism of action, multiple treatment options, and the
presence of a clinical biomarker. There are 21 approved cancer therapies which either require or
recommend a biomarker/diagnostic before prescription, comprising nearly two-thirds of all
biomarker/diagnostic therapies2. Moreover, the high cost (often greater than $100,000 for a
single course or year of treatment) and rate of severe toxicities in cancer treatment, and the
differential benefit between patient populations, can incentivize payers to reimburse diagnostics
which can cost thousands of dollars3.
While targeted therapies have had a significant impact and even transformed some cancers into
chronic "maintenance" conditions, many tumors relapse and become symptomatic despite
optimal treatment. Causes of relapse include:
e Drug modification (chemically altering the drug to an inert substance)
e Prevention of drug uptake (often a down-regulation of carrier proteins)
e Drug efflux (extruding the drug from the cytosol and preventing the attainment of
therapeutic concentrations)
e Increased repair of drug damage (undoing the damage done by chemotherapy)
e Substrate alteration (preventing the drug from binding its intended target)
e Insensitivity to apoptosis (reducing susceptibility to chemotherapy)
e Proliferation through a new pathway (necessitating at least one new therapy)4
A mutation that causes a tumor to resist treatment that it had previously responded to is hereafter
referred to as an "escape mutation" and the ongoing process of drug-induced genetic change as
"tumor evolution."
One of the greatest successes of targeted therapy was the introduction of Novartis' Gleevec
(imatinib mesylate), a tyrosine kinase inhibitor (TKI) that targets the cause of most CML, the
BCR-ABL kinase. It was approved in May 2001 for the treatment of chronic myeloid leukemia
(CML)5 and transformed not only the clinical treatment of the disease but the economics of
treatment. A relatively small disease (5,000 new U.S. patients per year) could be treated as a
near-lifelong chronic condition with premium pricing, translating to mega-blockbuster revenues
(estimated worldwide sales of $3.2 billion in CML in 2010)6. Longer-term data have borne out
the promise of Gleevec, with a majority of patients still adequately treated at seven years from
disease diagnosis. In the meantime, two more TKIs have been approved for CML: Novartis'
Gleevec follow-on Tasigna (nilotinib) and Bristol-Myers Squibb's Sprycel (dasatinib). Both
garnered approval for later-line disease before moving into the 14-line setting. However, some
mutations confer resistance to Gleevec, Tasigna and Sprycel, most notably the T3151 mutation in
the BCR-ABL kinase domain.
While the 1 s-line market may be the largest and most profitable segment of CML treatment, a
considerable unaddressed market for 1 s-line failures will emerge over time. Moreover, a drug
manufacturer seeking a label for patients in later-line settings may gain approval with smaller
and shorter studies, and enjoy premium pricing and regulatory treatment (such as orphan drug
status). Given the presence of resistance mutations in 2 "d- and 3'd-line disease, a label to treat
CML with certain particularly difficult-to-treat mutations could theoretically gain rapid adoption.
It remains to be seen if the streamlined clinical and regulatory path and premium pricing can
outweigh the smaller patient population and requirement for a companion diagnostic.
I examine this idea through the following methods:
1. Deep-dive case study in CML. Most patients who receive any one of the three approved
TKIs at the earliest ("chronic phase") stage will have well-controlled disease for many years,
while others will either lose response or progress to a more advanced phase of disease. A subset
of these will manifest mutations that render their tumor resistant to all three drugs. I use
published data on the epidemiology of CML, analyst sales estimates, peer-reviewed efficacy and
safety data, and parameter estimates from thoughtleaders to construct a state-transition model of
the diagnosis, treatment and prognosis of CML. This is then translated to a profit and loss
statement (for commercialization in the US and Europe) to determine the net present value
(NPV) of a hypothetical drug geared to treat CML with an otherwise untreatable resistance
mutation.
2. Sensitivity analyses. Using the model developed in the first part, I modify certain key inputs
in order to determine which factors most influence the profitability of the hypothetical candidate.
Key factors including frequency of the untreatable mutation, drug pricing, discount rate,
development conditions and long-term data associated with the three approved agents can greatly
influence the profitability of the hypothetical candidate.
3. Qualitative supplement. In addition to providing modeling estimates, interviews with various
constituencies served to confirm the critical dynamics around the CML market and provide
qualitative insight. Interviews were conducted with leading clinicians, investment analysts, key
clinical, regulatory, and commercial personnel at biopharmaceutical companies, payers and basic
scientific researchers.
4. Extensions and applications. I conclude by discussing the further uses of a transition-state
patient flow model. Many subacute and chronic diseases are divided into stages with differential
prognoses for death, complication, progression and recovery, and long-term data could allow for
modeling in the same fashion as this model does for CML.
Scientific overview
Targeted therapies have advanced hand-in-hand with cancer biology in general and knowledge of
perturbations in cancer signaling pathways in particular. Over time, many tumors overcome
signaling pathway inhibition through resistance mutations. Certain evolved genotypes are
increasingly recognized as problematic and possibly worthy of investment. I examine the science
of cancer signaling, inhibition and escape from inhibition, with a focus on the biology and
treatment of CML.
Importantly, the forthcoming modeling analysis takes a "black box" approach to the
development of resistance. The timing (i.e. prevalent at diagnosis or developed during treatment)
and precise causes of resistant mutations are unknown and current diagnostics are inadequate to
detect all potential clones in a tumor sample. Moreover, mutational analysis is not conducted in
trials until failure or progression (defined later in this section) occur. Thus, the modeling and
analysis do not depend on how a mutation arose, but only on the fact that a mutation arose during
serial treatment.
Implications of cancer as a genetic disease
Dr. I. Bernard Weinstein describes tumorigenesis as a sequential process involving the
mutational activation of growth-promoting genes (oncogenes) and mutational inactivation of
growth-suppressing genes (tumor suppressors), as well as epigenetic (non-mutational)
abnormalities that lead to increased or decreased expression of these genes 7. This process has
been shown to occur in reverse as well, as studies in multiple tumor types have shown that
turning off critical oncogenes (including myc, Her-2/neu, K-ras and cyclin Dl) or introducing
natural tumor suppressors (including p53, retinoblastoma suppressor (Rb) and APC) causes
cancer cells to cease proliferating and undergo apoptosis. Together, these observations reinforce
the scientific view of cancer as a disease of uncontrolled cell growth secondary to abnormal
genetic changes.
The nature of escape mutations
While patients with advanced and highly resistant solid tumors show drastic responses to single
pathway inhibitors, many of these tumors rapidly recover after several months on therapy. The
precise nature of a tumor's "escape" from therapy has not yet been fully elucidated, but many
theories exist.
A tumor will have accrued many mutations and lack many safeguards against further DNA
mutations by the time it becomes clinically symptomatic. Therefore, it is likely to continually
accrue new mutations as well as aneuploidy (changes in chromosomal number),
endoreduplication (duplication of the genome without mitosis), chromosomal deletions and
8
chromosomal translocations as it grows and spreads . If a given mutation compromises essential
cellular machinery or otherwise impairs survival, the cell will die. If not, a given mutation may
be categorized as a "driver" mutation (which drives cell proliferation) or a "passenger" mutation
(which does not).
The nature and genesis of escape mutations has not been determined and is a topic of scientific
debate. One hypothesis holds that a tumor presents clinically as a homogeneous entity without
the resistant clone present, while the resistant mutation that evades treatment occurs only after
selection pressure is provided via the drug. Another assumes a heterogeneous tumor with a large
burden of wildtype cells and a small but undetectable number of resistant cells that proliferate
only after the drug reduces the wildtype tumor burden. More sensitive tumor assays at baseline
that can detect minute quantities of heterogeneous tumor cells would be necessary to distinguish
the two.
In addition, there is a population of "stem cells" that breed further leukemia cells that persist
even with targeted therapy. The "log-kill" hypothesis of cell-killing agents states that each dose
of medication kills a fixed percentage of cells; under this hypothesis, leukemic stem cells are
simply BCR-ABL-expressing hematopoietic progenitors (in contrast to the more differentiated
tumor cells observed in CML) that do not receive adequate levels of TKI. Moreover, it has been
shown that BCR-ABL-expressing progenitor cells persist even in patients who respond to
Gleevec 9. Another hypothesis is that leukemic stem cells express BCR-ABL but have some other
characteristic that renders them insensitive to TKIs. For example, one study suggests that stem
cells undergo autophagy (a state of metabolic inertia in which a cell degrades internal
components) that renders them resistant to TKIs'0 .
While cancer stem cells have been best characterized in hematologic malignancies, similar
observations have been made in solid tumors. For example, samples of breast cancer tissue
revealed a subset of cells with characteristics of bone marrow stem cells (bone marrow stem cells
may proliferate in conditions of both normal physiology and cancer)".
Evidence of oncogene addiction
It has been observed that inhibition of even one mutation that the tumor depends on to stay
malignant can be sufficient to inhibit profoundly or even eradicate the tumor 2 . The theory of
oncogene addiction postulates that although tumor cells may have many genetic aberrations,
inhibiting one gene or pathway can prevent the cell from proliferating further.
Further evidence of oncogene addiction lies in the fact that so-called "escape mutations" (that is,
mutations that allow a tumor to evade therapy) most frequently occur in the original mutated
pathway' . In particular, studies of CML and epidermal growth factor receptor (EGFR)-
overexpressing non-small-cell lung cancer are associated with specific resistance mutations that
confer insensitivity to pathway inhibitors. For example, resistance to TKIs in CML is commonly
associated with specific mutations in the BCR-ABL kinase, and several tumor types develop
resistance to EGFR inhibition by gaining constitutive activity of the downstream signaling
molecule Ras.
While the precise molecular and cellular mechanisms of oncogene addiction have not been
determined, several theories exist as to why it has been observed. Dr. Restifo details three major
theories:
e "Dominant oncogene": One of the first theories of oncogene addiction held that tumor
cells receive growth signals through multiple pathways but preferentially proliferate
through a single pathway. Over time, mutations and epigenetic changes silence other
pathways and leave it dependent on one. Thus, inhibition of the dominant pathway
renders the cell unable to proliferate and leads to apoptosis.
e "Cumulative mutations": In this theory, some driver mutations are beneficial in the
presence of a certain second mutation, but harmful on their own. In this case, inhibiting
one mutated pathway leaves the cell with a harmful mutation that leads to senescence or
death.
e "Oncogene amnesia": This theory holds that there is a balance of pro- and anti-apoptotic
factors in the cell, with the latter mediated by oncogenes and overriding the former
during proliferation. Therefore, once the oncogene is inhibited, the balance tilts in favor
of pro-apoptotic factors and leads to cell death.
It logically follows that a drug which inhibits the responsible pathway can significantly slow or
even halt tumor growth, thus potentially 1) allowing the immune system to better control the
tumor burden; 2) reducing the rate of tumor replication, mutation, and resistance development;
and 3) increasing the efficacy of other anticancer therapies. In particular, combinations of
pathway inhibitors which cover the original tumor and likely mutations could work
synergistically to delay the time to drug resistance, similar to the use of combination therapy to
treat HIV or tuberculosis.
Scientific case study: CML
The "arms race" of cell proliferation, pathway inhibition and escape mutation has been well-
studied in CML, a slow growing hematologic cancer characterized by abnormal proliferation of
myeloid cells and progenitors. The availability of long-term outcomes data, its well-
characterized three phases of disease and problems of specific drug-resistant genotypes permit
use of a transition state model to study a clinically and commercially relevant question.
CML is associated with a mutated gene knows as the breakpoint cluster region-Abelson
leukemia virus (BCR-ABL) fusion oncogene, the result of a translocation between chromosomes
9 and 22 [t(9; 22)(q34;q 11)] termed the "Philadelphia chromosome" (Ph+) '5. Alone, the ABL
tyrosine kinase is highly regulated; coupled to BCR, the fused oncogene encodes for a
constitutively active 210 kDa tyrosine kinase. The BCR-ABL kinase phosphorylates many
downstream signaling molecules, including those in the Ras/Raf/MEK/ERK, Jak/Stat and
phosphoinositol-3-kinase (PI3K)/Akt signaling pathways' 6. This activity within a hematopoietic
stem cell (HSC) allows it to proliferate and displace normal HSCs and is sufficient to render the
17HSC cancerous
Though 95% of CML cases express BCR-ABL, the two are not synonymous. So-called "Atypical
CML" presents without detectable BCR-ABL, although many of these patients have other
chromosomal rearrangements that could inhibit detection of the actual t(9; 22) translocation, and
it is debated whether the remainder have CML or a different myeloproliferative disorder known
as myelodysplastic syndrome. Additionally, BCR-ABL may be present in a B-cell acute
lymphocytic leukemia (ALL) termed Ph+ ALL which carries an especially poor prognosis and
requires intense multi-year chemotherapy' 8 .
The disease progresses in three phases, with an average untreated survival of approximately three
years from diagnosis:
e The chronic phase (CP) involves the transformation of an HSC and increase in the
number of myeloid cells within the appropriate hematopoietic tissues (blood, liver,
spleen, bone marrow). Compared to other leukemias, these cells are relatively mature
with predominant neutrophils, and lesser quantities of basophils and eosinophils.
Clinically, most chronic phase patients present with left upper quadrant pain,
splenomegaly, pallor, loss of appetite, fatigue, and bone pain of slow onset. Diagnosis is
confirmed by laboratory abnormalities include progressively increased white blood cell
count, elevated platelet count, hypercellular bone marrow with Philadelphia
chromosome-positive cells, and blasts in the peripheral blood. Approximately 90% of
patients present in this stage, and this fraction is likely increasing due to earlier diagnosis.
e Accelerated phase (AP) disease is poorly defined, and occasionally argued to be an early
form of blast crisis 19. Patients often develop a fever and night sweats, and additional
cytogenetic abnormalities. Most notably, increases in activity of the Wnt pathway
(through beta-catenin) and the hedgehog pathway have been observed, as are trisomy 8,
trisomy 19, additional copies of the Philadelphia chromosome and isochromosome 17q.
* The final stage of disease is the blast crisis (BC), in which a high percentage of blasts
occur in the peripheral blood. This stage resembles an acute leukemia and may be either
myeloid or lymphoid in appearance. Genetic aberrations include those observed in AP
disease as well as dominant negative mutations in transcription factors required for
differentiation, mutated p53, c-Myc amplification, and Rb deletion.
Table 1: WHO definitions of accelerated phase and blast crisis20
Accelerated Phase Blast Crisis
Blasts (myeloid or lymphoid progenitor cells) Blasts comprising 20% of peripheral white
comprising 10-19% of peripheral white blood blood or bone marrow cells
or bone marrow cells
Clusters of blasts in the bone marrow
Basophils comprising 20% of peripheral
white blood cells Development of a solid focus of leukemia cells
outside the bone marrow
Platelet abnormalities: thrombocytopenia
(platelets <100,000/p 1) unrelated to therapy or
thrombocytosis (platelets >1,000,000/pl)
unresponsive to therapy
Increasing spleen size and white blood cell
count despite therapy
Clonal evolution
CML treatment before and after targeted therapy
CML treatment has evolved significantly over time. Since the 1950s, traditional cytotoxics
including busulfan (an alkylating agent) and hydroxyurea (a ribonucleotide reductase inhibitor)
were used to lower white blood cell counts, and are occasionally still used today in blast crisis,
later-line patients, or to bring white blood cell counts under control prior to initiating targeted
therapy.2 Immunotherapy was introduced with trials of interferon-a in the 1980s, both alone and
in combination with cytosine arabinoside (termed "ara-C", an antimetabolite). This combination
was the CML standard of care before the introduction of targeted therapy.
The first approved targeted therapy for CML was Novartis' Gleevec (imatinib mesylate),
approved in May 2001. A competitive inhibitor of the ATP binding site of the BCR-ABL kinase
(with activity against platelet derived growth factor (PDGF) receptor and c-Kit), Gleevec quickly
became the new standard of care after showing significant benefits over interferon-a + ara-C.
This benefit has since been shown to be durable (81.2% v. 60.6% progression free survival at
seven years, defined as freedom from death, loss of response, progression to AP/BC, or
increasing white blood cell count) 2, with a generally tolerable side effect profile that includes
edema, cramps and rash, with approximately 4% of patients discontinuing treatment. These
strong efficacy results were reproduced even in clonally evolved accelerated phase and blast
crisis disease, lending further weight to the hypothesis of oncogene addiction.
The second BCR-ABL kinase inhibitor approved was Bristol-Myers Squibb's Sprycel
(dasatinib), approved in June 2006. In addition to binding BCR-ABL kinase with 325-fold
potency compared to Gleevec, Sprycel binds SRC family kinases and may theoretically prevent
tumors from developing resistance through this pathway. Its pivotal trial in chronic phase CML
showed improved rates of complete cytogenetic response (77% v. 66%) and major molecular
response (46% v. 28%), two important measures of response, compared to Gleevec . The major
side effect of Sprycel is pleural effusion, and approximately 6% of patients discontinued
treatment.
The most recent drug approved for CML was Novartis' Tasigna (nilotinib), which was approved
in October 2007. Unlike Gleevec, Tasigna binds to and stabilizes the inactive conformation of
the BCR-ABL kinase (20-30-fold affinity relative to Gleevec) and like its predecessor also
inhibits PDGF receptor, c-Kit, colony stimulating factor-I (CSF- 1) receptor, and discoidin
domain receptor (DDR). It also showed superiority to imatinib in complete cytogenetic response
(80% v. 65%) and major molecular response (44% v. 22%)4. Like the others, Tasigna is well
tolerated, although the drug has to be taken twice daily, and is known to prolong the QT interval
and thus be potentially arrhythmogenic.
These three drugs are approved to treat all phases of disease, with the latter two recently earning
25approval as first-line treatment for chronic phase disease
Table 2: NCCN response criteria26
Complete Hematologic Response
(CHR)
Normalization of peripheral blood counts with white blood
cell count < 10,000/pl
Platelet count < 450,000/pl
No immature cells in peripheral blood
No signs of disease including palpable splenomegaly
Same as Complete Hematologic Response, except:
Immature cells in peripheral blood
Platelet count <50% of pretreatment count but <450,000/pl
Palpable splenomegaly <50% of pretreatment extent
Partial Hematologic Response
(PHR)
Cytogenetic Responses (CyR) Relates to fraction of Philadelphia-chromosome positive
chromosomes (observed at metaphase):
Complete - 0% (CCyR)
Partial - 35% (PCyR)
Major - CCyR or PCyR
Minor - < 65% (mCyR)
Complete Molecular Response No BCR-ABL mRNA detectable by RT-PCR
(CMR)
Major Molecular Response <0. 1% ratio of BCR-ABL mRNA to housekeeping genes
(MMR)
Table 3: Treatment goals 2
Optimal (continue Suboptimal (variable- Failure (re-evaluate, test
treatment as is with switch patient if significant for mutations and switch
periodic monitoring) adverse events) treatments)
3 mos CHR + mCyR (or better) CHR without CyR Less than CHR
6 mos PCyR (or better) CyR less than PCyR No CyR
12 mos CCyR (or better) PCyR Less than PCyR
18 mos MMR (or better) CCyR without MMR No CCyR
At any Stable or improving Loss of MMR, clonal Loss of CHR, loss of
time MMR evolution CCyR, clonal evolution
Tackling resistance
While these targeted therapies have eclipsed older chemo- and immunotherapies in both efficacy
and safety, resistance remains a problem. Bixby et al detail several potential causes 28:
e BCR-ABL kinase domain mutations: It is believed that most patients who develop
resistance do so because of BCR-ABL kinase domain mutations (approximately 50% of
patients with CML resistant to Gleevec). In chronic phase, mutations develop over a
period of years (16% over 42 months in one study); in accelerated phase and blast crisis,
mutations become clinically apparent much sooner29. However, the precise causes of
mutation have not been determined (though are speculated to include induced expression
of mutagenic enzymes, altered mechanisms of DNA repair or generation of reactive
oxygen species).
e BCR-ABL mutations outside the kinase domain: Half of patients who fail TKI
treatment do not show mutations in the BCR-ABL kinase domain, and many are believed
to have mutations elsewhere in the gene.
* BCR-ABL amplification: While some studies have shown increased expression of the
BCR-ABL gene, and Gleevec dose escalation is often used when the initial dose fails to
produce a desired response, this is believed to be relatively uncommon.
e Drug efflux: BCR-ABL kinase inhibitors act within the cell, and imatinib, dasatinib and
nilotinib are all known to be substrates of drug efflux pump P-glycoprotein3 0 31 . However,
P-glycoprotein expression has not been observed to predict resistance in human studies.
* Other signaling pathways: Cancer signaling pathways are often complex and aberrant,
and several mutations have been observed in BCR-ABL kinase inhibitor resistant CML
including Lyn, Src, and Erk2.
e Epigenetic alterations: Since the BCR-ABL gene is commonly methylated, physicians
will occasionally use hypomethylating agents such as Eisai's Dacogen (decitabine) to
treat accelerated phase disease . Small studies of decitabine showed some hematologic
and cytogenetic responses in Gleevec-resistant disease across all disease phases 3 .
Resistance mutations
The most commonly observed mutations occur in the ATP binding domain and affect residues
which can either block the drug from binding or fail to form crucial hydrogen bonds with the
drug. The most clinically concerning mutation is the T3151 mutation, in which the bulky
isoleucine side chain blocks the site to which TKIs bind and renders patients resistant to all three.
Others of note include M244V, G250E, E255K/V, M35 IT and F359V, which together account
for an estimated 85% of resistance mutations 4 .
Scientific case study: other solid tumors
The success of targeted therapies for several solid tumors further underlines the theory of
oncogene addiction. These generally have more mutations than hematological malignancies
before they become clinically apparent, but have shown susceptibility to single pathway
inhibitors. Three other case studies are detailed below:
HER2
The HER2 protein (also known as ErbB-2, CD340 or p185) is a 185 kDa transmembrane growth
factor receptor of the EGFR family and is overexpressed in approximately 25% of breast
cancers". While the EGF ligand family cannot activate HER2, other receptors in the same family
can dimerize with HER2 and lead to signal transduction via the PI3K/Akt pathway and mitogen-
activated protein (MAP) kinase pathway, and production of pro-angiogenic vascular endothelial
growth factor (VEGF) 36. HER2-overexpressing tumors are notoriously aggressive and insensitive
to hormonal methods of treatment.
Two approved drugs are known to inhibit this pathway: Roche's Herceptin (trastuzumab, a
monoclonal antibody) and GlaxoSmithKline's Tykerb (lapatinib, a small molecule dual
EGFR/HER I and HER2 tyrosine kinase inhibitor)3738. Herceptin was approved in 1998 and has
more extensive available data, including robust efficacy in metastatic (progression free survival
of 7.2 months in combination with chemotherapy vs. 4.5 months for chemotherapy alone) and
adjuvant (33-52% reduction in recurrence following surgical removal) settings.
Tykerb illustrates the utility of oncogene addiction more purely as it does not function through
immunological mechanisms, and has shown efficacy in combination with chemotherapy in
treating Herceptin-resistant disease.
EGFR
Often called HER 1 or ErbB- 1, EGFR binds a wide range of growth ligands to stimulate signal
transduction and tumor proliferation. Similarly to family member HER2, EGFR signals for
survival and proliferation through the PI3K/Akt and MAPK pathways. Signaling through this
receptor has been implicated in non-small-cell lung cancer (NSCLC), colorectal cancer (CRC),
pancreatic cancer, squamous cell carcinoma of the head and neck (SCCHN) and brain cancer.
There are four approved drugs that inhibit this pathway: two TKIs, AstraZeneca's Iressa
(gefitinib, approved in 2003) and Roche/OSI's Tarceva (erlotinib, approved in 2004) and two
monoclonal antibodies, Eli Lilly's Erbitux (cetuximab, approved in 2004) and Amgen's Vectibix
(panitumumab, approved in 2006).
B-Raf
The evolving B-Raf inhibitor story illustrates both the promise and challenges of targeted
pathway inhibitors. B-Raf is one of three Raf proteins, also known as MAP kinase kinase kinases
(MAPKKK), which serve as signal transduction kinases in the MAPK pathway and regulate cell
division, differentiation and secretion39 . Additionally, melanoma is notoriously resistant to
chemotherapy-melanocytes evolved to sense and repair DNA damage and thus it is expected
that a melanoma will resist DNA damaging agents effectively40.
One of the most exciting oncology clinical candidates in development is Plexxikon's (recently
acquired by Daiichi) B-Raf inhibitor PLX4032 for the treatment of metastatic melanoma with the
B-Raf V600E mutation. An open label, multi-center 132 patient study shows a response rate of
52% including 2% complete response (no evidence of disease) and 50% partial response (tumor
shrinkage of at least 30%), with an additional 30% showing stable disease 41. However, many of
these responses were short lived. A study by Wagle et al. showed that one patient developed
42resistance after developing a C 12 1 S mutation of the downstream signaling molecule MEK
Market overview
The question that I will use the model to answer-will a hypothetical drug candidate aimed at a
particular resistance mutation be sufficiently attractive to drug developers-is most relevant to a
well-studied market. While some resistance mutations (including certain K-Ras mutations in
colorectal and pancreatic cancers) are present at baseline, questions of acquired resistance are
more complex and lend themselves to transition-state methodologies.
Classifications of targeted therapy
According to a Cowen & Co. analyst report, oncology/hematology is the largest single disease
area by product sales with 2009 worldwide sales of $71.3 billion (20% of the worldwide
biopharmaceutical market), expected to increase to 2015 worldwide sales of $97.0 billion (5%
compound annual growth rate (CAGR)). Of these, targeted therapies comprise $28.4 billion or
40% of the total oncology/hematology market, the largest single share of any drug type.
Targeted therapies are frequently divided into monoclonal antibodies and small molecules, each
with advantages and disadvantages relative to the other.
The former are very specific for the chosen protein (and thus for cells that express that receptor)
and act via multiple mechanisms of action including 1) sequestering the ligand (Roche's anti-
VEGF antibody Avastin (bevacizumab) is approved for several cancers including CRC, NSCLC,
breast cancer, glioblastoma and kidney cancer)", 2) preventing the ligand from binding to the
targeted receptor, 3) antibody dependent cellular toxicity (triggering tumor cell destruction by
mediating phagocytosis), 4) complement dependent cytotoxicity (in which the antibody fixes
complement leading to tumor cell lysis) and 5) antibodies may be conjugated to a cytotoxic or
radioactive payload to deliver a "smart bomb" (Roche's drug candidate trastuzumab-DMI
consists of Herceptin conjugated to a cytotoxic and has shown superior response rate compared
to Herceptin in Phase II trials)45 . On the other hand, these drugs must be infused over a long
period of time and many risk triggering allergic reactions. With respect to efficacy, a mutation
within the intracellular signaling machinery will also render the antibody ineffective. They are
also generally more expensive than small molecules. Some of the greatest market successes
including Roche's Rituxan (2009 worldwide sales of $5.6 billion), Roche's Herceptin (2009
worldwide sales of $4.8 billion) and Eli Lilly/Merck KGaA's Erbitux (2009 worldwide sales of
$1.6 billion) come from this category.
Small molecules generally inhibit the intracellular signaling apparatus that triggers cancer cell
survival and proliferation. Many TKIs inhibit a wide range of signaling kinases, including
Pfizer's Sutent (sunitinib), which has activity against platelet derived growth factor receptors
(PDGFRa and PDGFRO), VEGF receptors 1, 2 and 3, KIT, Fms-like tyrosine kinase-3 (FLT3),
colony stimulating factor receptor Type 1 (CSF- 1 R) and glial cell-line derived neurotrophic
factor receptor (RET)47, while others are much narrower in spectrum including Roche/Astellas's
Tarceva (erlotinib) which only meaningfully inhibits EGFR48 . Other small molecule targeted
therapies include hormonal agents which inhibit estrogen or androgen synthesis or receptors, or
immunomodulators and antiangiogenics with less-understood mechanisms of action, such as
Celgene's Thalomid (thalidomide) and Revlimid (lenalidomide). While they can inhibit a
broader range of kinases, this can potentially translate to side effects, and tumors may evolve to
"work around" inhibition. Top sellers include Gleevec (2009 worldwide sales of $3.9 billion)
and AstraZeneca's Arimidex (anastrozole, 2009 worldwide sales of $1.7 billion).
Case study: HER2-overexpressing breast cancer
One of the first success stories of stratified medicine involved the development and
commercialization of Herceptin for the treatment of HER2-overexpressing breast or gastric
cancer. Herceptin was first approved in the U.S. in 1998 for the treatment of metastatic HER2-
overexpressing breast cancer, and U.S. sales increased at a steady rate from $184 million in 1999
to $479 million in 200449. The market for metastatic breast cancer is significant for its
prevalence, but only -25% of breast cancer patients (10,000 in the U.S.) are Herceptin-eligible,
and the drug is only dosed every three weeks until disease progression (6.7-7.6 months in first-
50line disease, and likely lower in previously treated disease)
A major inflection point occurred when strongly positive results in the adjuvant setting (post-
surgical, to prevent recurrence and metastasis of residual disease) drove 2005 U.S. sales to $747
million and 2006 sales to over $1.2 billion. Increased screening for breast cancer is likely to
contribute to earlier detection and diagnosis in the adjuvant setting (approximately 25,000
women are believed to undergo adjuvant chemotherapy for breast cancer), and the labeled
duration of treatment of 52 weeks translates to a richer market opportunity.
Case study: BCR-ABL kinase inhibitors for CML
BCR-ABL kinase inhibitors for the treatment of CML garnered an estimated $4.2 billion in 2010
worldwide sales, a seemingly disproportionate sum for a disease that affects approximately
100,000 individuals in the U.S. and EU and only 12,000 newly diagnosed individuals per
year52. Despite its small size, this market has the potential to be extremely profitable due to
highly differentiated efficacy translating to premium pricing, small sales force requirements to
market this class effectively, and lifelong requirement (so far) to receive the drug.
Approximately 75% of Gleevec sales (estimated $3.2 billion in 2010) come in CML, with the
remainder in a sarcoma known as gastrointestinal stromal tumor (GIST) in which it functions as
a c-Kit inhibitor, or in several rare hematologic malignancies. Gleevec's convenient once-daily
oral dosing and demonstrated efficacy over several years of treatment have made it the standard
of care for CML (especially chronic phase CML) for some time
The second-generation TKIs Sprycel and Tasigna have been approved in 2006 and 2007 for
Gleevec-resistant disease, respectively, and more recently for first-line use. Each showed
superiority to Gleevec at 12 or 24 months in its Phase III chronic phase CML pivotal trial, but
has not been studied long enough to show the long-term efficacy profile. Nonetheless, they are
regarded as likely to prove more efficacious over the long term, and thus preferred for younger
patients or more aggressive disease. In addition, both have differentiated resistance profiles
compared to Gleevec, though certain BCR-ABL kinase domain mutations (most notably T3151)
will render both drugs ineffective. 2010 sales of Sprycel and Tasigna were $399 million and
$576 million, respectively, but are expected to increase to $1.9 billion and $1.4 billion by 2016.
The next wave of TKIs has been deemed "third-generation TKIs" and includes the following:
e Pfizer's bosutinib is a BCR-ABL and Src kinase inhibitor for which regulatory filings
are expected in 2011. Trials of bosutinib in 2"d- and 3'd-line therapy showed efficacy in
chronic phase CML56 . However, its Phase III trial in 14-line chronic phase CML failed to
show a statistically significant improvement in its primary endpoint of CCyR against
Gleevec (70% vs. 68%), though it showed an improvement in MMR (39% vs. 26%)
Ariad's ponatinib (formerlyAP24534) is a pan-BCR-ABL inhibitor, specifically
engineered with a triple carbon bond that enables it to avoid the bulky isoleucine side
chain and have activity in T3151 CML57 . It also inhibits FLT3 (common in acute myeloid
leukemia) and c-Kit, with some observed activity against VEGF, PDGF and fibroblast
growth factor (FGF) receptors, and the angiogenic protein Tie-2. While still early in
development, Phase I data from a dose-ranging study presented at the American Society
of Hematology (ASH) 2010 conference showed activity in a highly resistant population
of hematologic malignancies (mostly CML, with 95% resistant to at least 2 TKIs and
65% resistant to 3 TKIs). Ponatinib induced MCyR in all 9 patients with T3151 and
CCyR in 8 of those, and 66% and 53% respectively in the overall chronic phase CML
population despite many patients receiving less than the pivotal trial dose 58. The pivotal
Phase II PACE trail is currently enrolling patients in six cohorts, separated on the basis of
disease stage and T3151 mutation status.
Other drugs in the CML pipeline include the following:
e Chemgenex' omacetaxine (formerly homoharringtonine) is a subcutaneously-
administered inhibitor of the synthesis of oncogenic proteins including Mcl-1, Cyclin Dl
and c-Myc5 9 . Data presented at ASH 2009 showed MCyR in 41% of chronic phase CML
patients who had failed imatinib and presented with the T3151 mutation at baseline.
Regulatory filings are planned for 2H 2011.
e Deciphera's DCC-2036 inhibits BCR-ABL, Tie-2, LYN and HCK kinases by binding
the "switch region" to constrain them in an inactivate state, and thus is expected to have
efficacy against mutations which renders active-site binding TKIs (including all three
marketed agents) inactive**. A Phase 1/11 study in CML and Ph+ ALL is expected to
enroll 45 patients and be completed in September 201161.
* Other approaches. The hedgehog pathway receptor Smo (smoothened) has been
implicated as a cause of leukemic stem cells. A Phase 1/11 trial of Bristol-Myers Squibb's
Smoothened inhibitor in combination with Sprycel is ongoing in patients with a
suboptimal response to a prior TKI. Additional approaches include inhibitors of the
aurora kinases and heat shock protein (Hsp) 90.
Implications of oncogene addiction for commercial success
While oncogene addiction is a relatively recent development in cancer biology, its implications
are already widespread.
Genetically simple tumors are easier to control. One of the most important implications is the
relative ease of treating certain tumor types-including more genetically simple tumors with
fewer aberrations as in chronic phase CML-and the difficulty in treating more complex, heavily
mutated tumor types. It also explains the significant short-term disease control in other tumor
types coupled with the likelihood of relapse.
Molecular diagnostics will become increasingly important. Drugs such as Gleevec and
Herceptin require molecular diagnostics in order to be given to the right patients. However, as
tumors evolve and develop resistance, new diagnostic tests will be required in order to direct the
patient to the proper therapy for resistant or refractory disease. Ultimately, physician
thoughtleaders believe many tumors could be controlled by the process of 1) extensively
genotyping the tumor for a wide range of mutations and determining which pathways are most
active, 2) prescribing a personalized cocktail of pathway inhibitors to slow the tumor's growth
and impede the development of further mutations and 3) periodically checking the tumor to
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assure that it is under control
Efficacious drugs will be used for long periods of time. CML treatment is for life-at present,
physicians do not recommend stopping treatment for any reason, and 50% of patients with a
CMR (no evidence of BCR-ABL mRNA in the system) will relapse if they discontinue
Gleevec 63. Thus, an orphan cancer has become a >$4 billion dollar market, possibly increasing as
the Gleevec patent expires in 2015 and the more expensive Sprycel (24% price premium to
Gleevec) and Tasigna (33% price premium to Gleevec) take over.
Combination therapy may be on the horizon. The paradigm of combination therapy directed
as multiple aspects of an aberrant cell's machinery has been validated in infectious diseases. As
similar drug targets (often signaling molecules) are found in cancer, a personalized combination
could theoretically yield the same result.
One hurdle may be the regulatory element. The FDA has only recently approved trials of two
new agents in combination. Nonetheless the FDA has started to issue guidance on this matter.
Additionally, orphan drug status may be questionable for biomarker-defined subsets of larger
patient populations and is determined on a case-by-case basis (e.g. HER2-overexpressing breast
cancer received orphan designation but another subset may not show sufficiently differential
responses to be regarded as a separate indication)".
The model described in the next section uses CML as a model system to examine the scenarios
under which drugs for certain treatment-resistant genotypes may be commercially viable.
Model structure
In order to elucidate the impact of evolving tumors, I created a Microsoft Excel transition-state
model of the CML market to simulate changes in patient dynamics, drug use and physician
preferences over time. In this section I will detail the rationale behind the model, the model
structure, specific inputs and the reasons behind them, the model outputs, and finally the
limitations and future directions that further research would entail.
Why use a model to study tumor evolution?
It is becoming a standard practice in cancer targeted therapy clinical trials to collect and
genotype tumor samples. Some organizations such as Massachusetts General Hospital and the
National Cancer Institute even do so outside of clinical trials in order to better understand the
genetics of cancer65. Therefore, there is a growing database of information pertaining to evolving
tumor genetics and the clinical impact of drugs on this process.
I anticipate that the concept of tumor evolution will grow in commercial importance as
mechanisms of resistance to targeted therapy become elucidated. As certain drug-associated
mutations or other genetic aberrations gain notoriety, pharmaceutical manufacturers will need to
determine whether it may be profitable to develop a drug candidate that is effective against a
specific cancer genotype, weighing the concerns of a smaller patient population and need for a
companion diagnostic against the benefits of premium pricing, streamlined clinical and
regulatory development and less competition within the space.
This transition-state model takes publicly-available clinical trial and market data, and uses it to
quantify the market impact of evolving tumors. Additionally, a sensitivity analysis can be
conducted in order to determine the impact of changes in various inputs.
Why study CML?
CML is an ideal system to study tumor evolution for many reasons. First, its biology is relatively
well-understood and linked to a specific aberrant gene, of which specific mutations are
associated with drug resistance and disease progression. Several of these mutations (most
notably T3151) are recognized as major unmet medical needs by physicians and
biopharmaceutical companies alike 66. Thus it is an area of commercial as well as clinical interest.
Second, there is ample clinical data available on the long-term CML prognosis and the effects of
treatment. Gleevec product label data on mortality, drug failure, disease progression, and
tolerability extends to seven years from initial treatment, and studies on the newer agents
Tasigna and Sprycel are ongoing and likely to extend just as long in order to displace Gleevec as
the market leader.
Third, CML is well-suited for a transition state model. It is delineated into three phases with
distinct outcomes and symptoms among each, and well-studied transition probabilities between
them.
Model design
The end goal of the model is to determine the market for a hypothetical CML drug candidate that
is specifically designed to treat CML non-responsive to the three currently approved agents.
Inputs to the model are detailed as follows.
Table 4: Model in puts and outputs
Inputs Outputs
Demographics * Disease prevalence N/A
* Disease incidence
e Population growth rate
Financials e Past drug sales, used to estimate a * Sales of each of the three market
trajectory of use going forward drugs and the hypothetical
* Drug prices (branded and candidate over time, broken down
anticipated generic prices) by drug, phase and line of therapy
e Patent expiration times * Overall market size
* Project discount rate * Income statement translating to an
e COGS NPV of the candidate
d Estimated costs of drug marketing
Disease State * Disease stage at time of diagnosis e Change in CML patient population
c Outcomes of treatment (rate of over time
death, progression to next phase of * Number of patients receiving each
disease, drug failure without drug over time
progression, or intolerance) over
time
* Rates at which patients develop the
specified resistance mutation (in
this case, T3151)
Clinical e For each phase of clinical * Estimated development costs
Development development: * Risk-adjustment to NPV
o Probability of advancing to the
next phase
o Trial costs
o Duration of trial
Estimating the current market
The current CML patient population was obtained through published sales figures for CML
treatments Gleevec (adjusted for the estimated 75% share used to treat CML, with the remaining
25% used to treat other hematologic malignancies and gastrointestinal stromal tumor), Tasigna
and Sprycel, converted to estimated patient-years treated for the years 2006-201067. Sales
through 2011-2016 were obtained by taking consensus figures from analyst reports obtained
through Investext, and incidence rates of CML starting on each drug were modified to parallel
analyst estimates over this time68 and estimated prices (to manufacturer, rather than end-user)
were obtained through thoughtleader interviews. The hypothetical candidate was priced at a 30%
premium to the most expensive current agent (Tasigna) to reflect its efficacy in treating a highly
resistant genotype.
Similarly, patent information on each drug was readily available and incorporated into the model
(assuming full conversion from patented to generic agent at the time multi-source generics enter
69the market and a 90% price discount from branded to multi-sourced generic agent)
With respect to disease-specific figures, estimates of the prevalence and incidence of CML were
obtained through thoughtleader interviews and published sources70 '71 , with longer-term incidence
rates assumed to grow proportionally to the expected growth rate of the 65 years of age and older
patient population (1.99%). Rates of death, disease progression, drug failure without
progression and intolerance leading to discontinuation were obtained from peer reviewed
publications of clinical trial results or product labels. Where long-term results were not available,
I extrapolated progression rates by holding the ratios of progression/intolerance rates to a drug
with long-term data constant over time (that is, assuming that the drug tested has the same
pattern of efficacy as its comparator). Where drug failure with progression to accelerated phase
or blast crisis and drug failure without progression were not broken out, the ratio of the two was
assumed to be equal to that of the most relevant comparator (by drug and disease phase). The
hypothetical candidate was assumed to be used in combination with one of the three marketed
agents, and the combination was assumed to have the same efficacy against T3151 disease as the
least efficacious drug used for a given treatment line and disease phase, and similar safety (as
measured by rates of discontinuation).
I also assume that all patients with the covered mutation receive the drug, as it would be
marketed to a small specialist base that would be deeply involved with development of the drug
candidate.
Patient flows
Three sheets were created, one per phase of disease. Time progresses to the right, from the start
of the model in January 2007 until the end in December 2032 (representing the approximate start
of multi-sourced generics for the resistant candidate). Patients are introduced into the model on
diagnosis (at month zero, represented by the light green bar approximately halfway down the
illustration below is repeated for every drug). The first four columns represent a treatment
setting: Column A represents line of treatment (only TKIs considered), Column B represents
drug received (branded agents are referred to by their proprietary name e.g. Gleevec, generic
agents by their generic name e.g. imatinib), Column C represents disease phase (CP, AP, BC),
and Column D represents length of time in a given treatment setting (month 0 for newly
diagnosed or introduced to a given line of treatment, up to month 60+ for patients who have
adequately responded to therapy for 60+ months). Each treatment setting has a unique set of
associated transition probabilities.
The model assumes that the prevalent patient populations for each approved agent (Gleevec and
Sprycel) at the start of the first model year (2007) were evenly distributed by month since
approval. For Gleevec, chronic phase CML patients were distributed over 60 months (to
represent the favorable prognosis of this phase), accelerated phase CML patients, over two years,
and blast crisis CML patients, over six months (to reflect the poorer prognosis). Owing to
Sprycel's recent (late 2006) approval, all patients were assumed to be evenly distributed over six
months of chronic phase CML.
Every month, a patient may do one of the following:
e Respond to treatment, in which case she will stay in the same treatment setting
(effectively moving down and to the right in the model). For example, in Figure 1 there
are 708 patients in month 4 of treatment in June 2007 (6/2007), represented in cell K25.
Of these, 703 maintain response to therapy and "move" to July 2007 (7/2007) and month
5 of treatment, represented in cell L26.
* Become "intolerant." These patients move to 2L CP treatment and are not given a
probability of picking up the T3151 mutation as the drug was assumed to be efficacious in
suppressing disease, but not tolerable.
" Progress to the next phase. These move to 2L AP treatment and thus to the next tab of
the spreadsheet. They have a chance to pick up the T3151 mutation, which is a terminal
state (resistant to therapy and assumed to be treated with less-effective older therapies,
hematopoietic stem cell transplant (HSCT), rescue chemotherapy, or palliative care)
unless the hypothetical candidate has reached the market (in which case they are treated
with the candidate + the drug to which they lost response in order to maintain selection
pressure against all CML clones).
e Fail without progression. These patients move to 2L CP treatment and thus to a new
treatment setting within the CP tab. They start over at month 0 since studies in the 2 "d-
line measure response, failure, and intolerance from the time second-line treatment is
started, not disease diagnosis. They also have a chance to gain the T3151 mutation.
Importantly, not all drugs can be used in any order. Given the resistance spectrums of these three
agents, Gleevec can only be used as a 1 s-line treatment for any disease phase. Sprycel and
Tasigna can be used at any line of treatment.
Every month, the following statistics are tallied: number of patients receiving a drug, product
revenue in that month, number of drug failures (broken down into number of deaths,
progressions, failures without progression, and intolerant patients).
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*Any patient that fails to this line of therapy can gain the resistance mutation and become refractory to the three lines of therapy. At this point,
if the hypothetical candidate is approved, the patient receives the appropriate line of therapy in combination with the hypothetical candidate.
If not, the patient is refractory and placed into the absorbing state of "salvage therapy, HSCT, or death"
..... . . . ......
Salvage
theraff.
HSCT,
or death
Hypothetical candidate development
This model assumes the "present day" to be the beginning of 2011, at which point the company
is ready to initiate Phase I clinical development of both the hypothetical drug candidate and the
companion diagnostic that would be required to get a label to specifically treat T3151 disease.
Patient numbers and lengths of clinical trials required for approval were obtained from Sprycel
FDA Oncologic Drug Advisory Committee (ODAC) briefing documents73 , Ariad
Pharmaceuticals' PACE (Ponatinib Ph+ ALL and CML Evaluation) trial fact sheet74, and Kevin
Schulman's "Economics of Oncology Drug Development"7 . Probabilities of cancer drug
success were obtained from DiMasi's "Economics of New Oncology Drug Development,"
76.8% in Phase I, 59.4% in Phase II and 57.1% in Phase 1176I. Given the rarity of the T3151
mutation, high unmet medical need, and likely orphan drug status, I assume relatively small
clinical trials (Phase I - 60 patients, Phase II - 320 patients, Phase III - 500 patients), with
approval and launch occurring after Phase II (results in 2015, launch in 2016) but requiring a
confirmatory Phase III to keep the drug on the market (results available at the end of 2019). I
also assume an expedited regulatory review (12 months from end of Phase III to product launch)
to reflect not only priority review but FDA assistance in conducting the regulatory filing. Costs
of drug development were estimated on a per patient basis and assumed to be equal to the
average for oncology trials and obtained from the Institute of Medicine77. Costs of the
companion diagnostic, a relatively straightforward and already implemented quantitative reverse
transcriptase polymerase chain reaction (RT-PCR), were estimated from interviews. Many of
these assumptions will be varied in the sensitivity analysis.
To complete the project P&L statement, the cost of goods sold (COGS) was estimated at 5%79
(reasonable figure for a small molecule drug that does not require a complicated synthesis) and
SG&A spend for a 50-member sales force (small and decreasing over time to reflect a
concentrated prescriber base and increasing physician familiarity with the drug). Corporate tax
was estimated at 35%, with losses in the early years offsetting profits in the hypothetical
company's other operations. Profits were discounted at an appropriate real interest rate for a
large pharmaceutical manufacturer (11%), although a small biotechnology firm may use a larger
discount rate. This is also varied in the sensitivity analysis.
Model results
Base case results
I define the base case as the following set of variables. This represents one likely scenario that
could be encountered in drug development:
Table 5: Base case (*variable to be altered in sensitivity analysis)
Inputs
Demographics e 2010 CML prevalence (US/Europe): 100,000
e 2010 CML incidence (US/Europe): 12,000
e CML incidence growth: 1.99%
Financials e Past drug sales, used to estimate a trajectory of use going
forward (see graphs)
e Monthly drug prices:
Gleevec - $4,354
Sprycel - $5,417
Tasigna - $5,823
Candidate - $7,570*
* First fully generic year:
Gleevec - 2016
Sprycel - 2021
Tasigna - 2024
Candidate - 2033
* Project discount rate: 11 %*
* COGS: 5%
e Estimated costs of drug marketing: 50 reps @ $200,000 per rep
(decreasing over time)
Disease State e Disease stage at time of diagnosis:
CP - 90%
AP- 5%
BC - 5%
* Outcomes of treatment*
e Rates at which patients develop the specified resistance
mutation (in this case, T3151):
Following 1L - 5.16%*
Following 2L - 10.32%*
Clinical Development Phase I Phase II Phase III
Cost/patient* $65,500 $65,500 $72,500
# patients* 60 320 500
Duration* 1.75 2.50 3.72
(yrs)
Success prob* 76.8% 59.4% 57.1%
" Time from end of Phase III to launch: 1 year
" Companion diagnostic cost: $22,500,000
Figure 3: Base case development timeline
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Base
Case End of End of Regulatory End of confirmatory
Phase I Phase 11 Approval Phase IlIl
TKI use
The figure below illustrates the projected change in currently available TKI use over time, based
on the preferences and perceptions of physicians interviewed and the outcomes published in peer
review. Long-term data of these agents (except Gleevec) are not yet available, and pipeline
agents were not factored into the analysis. Both could have a substantial impact on the results of
the model.
Figure 4: Projected change in TKI use over time (arrows indicate generic entry)
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Figure 5: Projected change in branded TKI sales in CML over time (line stops at generic
entry)
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Change in CML population
The figure below illustrates the anticipated change in the prevalent U.S. and Europe CML
population over time. The smooth, linear increase indicates the relatively long lifespan of well-
treated patients with the disease. At its peak sales value (2015, with all agents available and no
multi-sourced generics on the market), the market size reaches $6.8 billion with approximately
115,000 patients on therapy. If the market becomes predominantly branded again (through
introduction of new therapies that significantly outclass the current drugs) at similar prices, the
market could increase to more than two-and-a-half times the 2015 figure as the patient
population approaches 300,000. This curve assumes that death rates observed in trials stay
constant over the long-term, when they may actually rise over time as other causes of death
become more likely.
Virtually all of the increase in the CML patient population is projected to come in chronic phase
disease, due to its good prognosis if properly treated and the poor prognoses of the two later
phases.
Figure 6: Projected change in total CML patient population over time
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Figure 7: Projected change in CML patients by disease phase over time
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The relevant population for the hypothetical drug candidate is CML patients who, following 1-
line or 2"d-line treatment, develop the T3151 mutation. In 14-line failures, this is estimated to be
5.16% of patients who develop resistance to Gleevec, in later lines of therapy, this resistant
80,81,82 d_fraction increases significantly . Assuming 2"-line rate of T3151 mutation equal to twice
the 1 "-line rate, I obtain nearly 500 patient-years of treatment in 2032, translating to a $45.3
million revenue run rate.
Figure 8: Projected change in T3151 patient population over time
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Financials
The "NPV rule" states that a company should invest in all projects with a positive NPV and no
projects with a negative NPV. Furthermore, if there are multiple exclusive project options with a
positive NPV, one should invest in the project with the highest NPV. With these assumptions, we
arrive at a risk-adjusted NPV for the hypothetical candidate of -$23.4 million for the pre-tax
NPV and -$15.2 million for the post-tax NPV, indicating an unprofitable project that should not
be undertaken. Depending on the manufacturer's size and resources, it is likely that it may have
more lucrative projects to fund than this one (e.g. spending more to boost sales of an existing
drug or developing another pipeline candidate) even if the hypothetical candidate were to show a
marginally positive NPV.
Sensitivity analysis
In this section, I determine the market's response to single variable changes in the model. While
multiple variable changes are more likely (and discussed later), this shows the relative sensitivity
to each.
Mutation frequency
One key variable is the frequency of the targeted mutation. Rates of acquisition of T315I were
determined from a Phase II study of Tasigna and may be different for other agents. Additionally,
despite my choice of T3151 for the hypothetical candidate (because it is recognized as an unmet
medical need and a mutation that resists all three approved agents), it is unlikely that a candidate
that treats a single, relatively rare mutation would be scientifically feasible (due to the nature of
the BCR-ABL ATP-binding domain), let alone commercially interesting. Another scenario
involves development of a TKI that covers a spectrum including T3151 and several other
currently unaddressed mutations. Since this is one of the most highly variable factors, I include a
sensitivity analysis of NPV vs. mutation rates in most analyses where it could be expected to
have a significant impact.
To account for this, I performed a sensitivity analysis in which I determine the NPV after
varying the frequency of mutations "covered" by the hypothetical candidate in both the 14 and
2nd line. Since less than 50% of l1t-line "failures" (both with and without progression) have
mutations in the BCR-ABL kinase domain and many of these may not be adequately treated by
the hypothetical candidate, I varied the 1 "-line "covered" mutation rate (as a percentage of total
I1"-line failures) from 1-20%. On the other hand, 2nd-line failures are more likely to have
significant resistance mutations and so I varied this figure from 5-100% (in 5% increments). The
results are indicated below:
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Increased drug failure rates
One potential upside scenario for the hypothetical candidate would occur if long-term data for
the three currently approved agents came in short of expectations. All else being equal, a higher
rate of failure for other agents would increase the number of patients who develop T3151. In this
scenario, I increase rates of death and failure (with or without progression) for all drugs to that of
the worst drug in each line of treatment and stage of disease. In this case, the NPV with pre-tax
dollars increases to -$11.5 million, and after-tax to -$7.45 million.
Notably, this scenario would significantly decrease the size of the overall market, since it would
provide payers with leverage to shift new patients to the least expensive (possibly generic)
treatment.
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Delayed time to market
A key downside risk to this project would occur if regulatory agencies demanded a full Phase III
trial prior to approval. Even in the base case, the rarity of the covered mutation could cause
delays in patient enrollment and push first product sales back from mid-2016 until the beginning
of 2021. In this case, the NPV with pre-tax dollars drops to -$38.8 million, and after-tax drops to
-$25.2 million, and only with much broader mutation coverage could it become even marginally
profitable.
Figure 11: Development timeline with Phase III results required for approval
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Favorable development with smaller trials
In the converse of the last scenario, the project could become more profitable if trial sizes were
reduced to account for the small population or the drug were shown to be so efficacious in a
pivotal trial that an interim data safety monitoring board halted the trial on the grounds that it is
unethical to administer placebo. To test a "favorable" scenario, I reduce Phase I, II and III study
populations by at least 50% (from 60 to 30, from 320 to 120, and from 500 to 200), and reduce
trial durations by 25% to account for the smaller populations.
As a trial halt for extreme efficacy (i.e. a data safety monitoring board rules that it is unethical to
administer the placebo or comparator treatment) is rare and difficult to predict, I do not
incorporate this.
Figure 13: Favorable development timeline
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Under this scenario, the drug is launched in early 2015, and the NPV increases to -$7.38 million
pre-tax and -$4.79 million post-tax. Varying the mutation rate yields the following.
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Favorable development with smaller trials and increased likelihood of success
In addition to reducing trial size and duration, this scenario increases the probability of trial
success by 10% at Phase I (to reflect the already high likelihood of Phase I success) and 20% at
Phase II and Phase III. Using these parameters and the base case mutation rate, I obtain a pre-tax
NPV of $0.88 million and a net income NPV of $0.57 million. This is nominally positive but
contains no "margin of error."
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Pricing
Newer targeted cancer drugs are known for a very high price point. Some new drugs are priced at
over $100,000 per year, often with a marginal median survival benefit. A drug like the
hypothetical candidate which has strong efficacy in a small subset of the CML population is less
likely to be prescribed off-label and could command premium pricing. On the other hand, payers
could regard it as another cancer drug and either refuse to reimburse (in some countries) or place
onerous restrictions including prior authorization.
In the base case, I assume the hypothetical candidate is priced at $7,570 per month ($90,840 per
year, translating to a 30% premium over the most expensive branded agent), with the net income
NPV at certain price points detailed below. Under the base case, an additional $1,000 per patient
per month adds $2.33 million to the NPV, with the NPV reaching zero at a price of $13,987 per
patient per month.
Figure 16: Net income NPV with varied pricing
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Discount rate
A commonly used real discount rate for large biopharmaceutical companies is 11 %, as in the
base case . However, smaller companies may have more restricted access to capital. Below, I
vary the cost of capital from 11-20%.
Figure 17: Net income NPV with varied discount rate
11% 12% 15% 18% 20%
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Multiple factor sensitivity
Generating a "clear winner"
Few of the above scenarios have a positive NPV, and those that do are only marginally positive.
To account for the "margin of safety" that most biopharmaceutical manufacturers would require
in order to invest in a project, I combine several of the positive factors discussed above including
price, discount rate, drug failure rates, favorable clinical development probabilities and trial
sizes. This will inform what assumptions are required in order to generate a highly positive NPV.
In this section, cells with an NPV over $100 million are indicated with blue text on a blue
background.
Positive drug failure rates, clinical development probabilities and trial sizes
Of the potential deviations from the base case, I view these three as the most likely as the most
likely to deviate in a manner that favors the hypothetical candidate. Under this case, the pre-tax
NPV rises to $20.7 million and the after-tax NPV rises to $13.5 million. Thus, the hypothetical
candidate would be a questionable investment (positive but small margin of safety) in the base
case, but an agent with broader coverage could be a clear winner in the later-line setting.
Mutation Frequency after First-Line Treatment
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Under these circumstances, the pre-tax NPV rises to $42.0 million and the post-tax NPV to $27.3
million. Even in this scenario, broader mutational coverage in 2nd- and 3rd-line setting is required
to for the hypothetical candidate to be significantly profitable.
Comparing this table to any of the previous tables, it appears as though multiple synergistic
factors would be required to generate a "significantly profitable" project. Given the superior data
on newer CML TKIs, a pricing/payer environment (particularly in Europe) that could exert
downward pressure over time and probable difficulties in enrolling sufficient numbers of patients
for a clinical trial, I believe it is highly unlikely that the hypothetical candidate be deemed
sufficiently profitable for investment.
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Limitations of the model
While systematizing published market data and clinical trial results to quantify the market is a
good surrogate for the way the market may evolve, there are a number of ways in which the
evolving CML market may deviate from the model.
* The CML treatment paradigm will continue to change. Sprycel and Tasigna have
been only recently approved for 1 "-line chronic phase use. While both demonstrated
superiority to Gleevec in this setting (where most treatment takes place) and are
perceived more favorably by oncologists, it is possible that many oncologists may
continue to start patients on the more familiar drug for which they are accustomed to
managing side effects8 4. Moreover, many treatment guidelines for response and failure
were developed with Gleevec treatment in mind. Use of the hypothetical drug candidate
would increase under slower-than-expected 2"d-generation TKI adoption due to the
higher failure rate with Gleevec.
" Data will evolve over time. This model relies on Gleevec data up to 60 months and
available Tasigna and Sprycel data up to 24 months, while the model projects the
hypothetical candidate through 20 years. Given the long life expectancy of an optimally-
treated CML patient, changing failure rates beyond 60 months could have a significant
impact on the number of failures. Moreover, CML is a disease of the elderly and very
long-term (10+ year) follow-up could yield increased rates of death from other causes.
Use of the hypothetical drug candidate would decrease with better long-term efficacy of
Tasigna and Sprycel.
e Off-label treatments and clinical trials not included. It is common practice for patients
with refractory or highly resistant disease to be placed on an off-label agent such as
decitabine, a chemotherapy regimen (particularly in blast crisis with rapidly-dividing,
chemotherapy-sensitive cells) or into clinical trials with highly variable efficacy and
safety. It would be difficult to predict and model the effects of these agents.
* Compliance not factored in. It is difficult to measure compliance with TKIs over time
and its effect on longer-term outcomes. Just as with other agents aimed at stopping cell
proliferation, a suboptimal level of drug caused by non-compliance could select for
resistant clones, which then proliferate in the presence of a drug that was formerly
effective. This can be particularly problematic in agents that must be taken more than
once per day (such as Tasigna) or that have more immediate unpleasant side effects.
Factoring in reduced compliance would increase the market for the hypothetical drug
candidate, as more patients would develop resistant disease.
e Trial enrollment could be erratic. On one hand, a drug aimed at treating the T3151
mutation could require relatively few patients in order to garner a regulatory approval,
even less than the "favorable development" scenario; on the other hand, it is often
difficult to predict how rapidly such a trial can enroll patients. Delays in bringing trial
centers online, or a lower-than-expected T3151 acquisition rate could reduce the value of
the drug candidate by protracting the time to market.
e Pipeline agents could disrupt the market. It is difficult to predict which agents will
ultimately receive regulatory approval. Pfizer's bosutinib may have activity against
certain resistant BCR-ABL mutants, but failed to achieve superiority to Gleevec in its
pivotal trial. Ariad's ponatinib showed strong activity against T3151 mutant CML in a
Phase I trial, even with many patients dosed well below the pivotal trial dose.
Deciphera's DCC-2036, which binds to the kinase switch region rather than the ATP-
binding domain, is also touted as having activity in T3151 resistant disease 5 . If either of
these latter two were to show robust efficacy in wildtype and T3151 disease, the market
for the hypothetical drug candidate would be effectively zero as physicians would rather
prescribe one drug with a full spectrum of action.
e Understanding of cancer biology is evolving. While CML is a comparatively "well
behaved" cancer with one principal disease-causing mutation, signaling pathways in
cancer are aberrant compared to normal cells. One thoughtleader mentioned that more
sensitive assays of a patient's BCR-ABL activity (by measuring levels of the
phosphorylated downstream protein CrkL) would be useful to determine drug effect and
86direct therapy 6. If such an assay could more effectively direct therapy, use of the
hypothetical drug candidate would decrease as patients can stay on earlier lines of
therapy for a longer period of time.
e Understanding of the biology of resistant mutations in CML is evolving. It has not
been determined whether: 1) resistant mutations are present at the onset of disease but
grow at a slower rate than the wildtype disease (and are suppressed by the wildtype) or 2)
only the wildtype is present at baseline, and oncogenes continually mutate and new
resistant mutations constantly emerge. In scenario #1, a more sensitive BCR-ABL
genotyping assay could determine which drug (or possibly a combination thereof) is most
effective and which patients are more likely to develop resistant mutations. These
patients could be treated with a combination of Gleevec/Tasigna/Sprycel + hypothetical
candidate at I s-line, which would greatly expand the market. Scenario #2 is more
accurately reflected in the model, as it assumes a random chance at each stage that a
patient will develop the resistance mutation that the hypothetical candidate covers. The
oncologist and patient would need to remain constantly "on guard" for the emergence of
resistant disease.
Qualitative findings
I interviewed various stakeholders to confirm the critical dynamics of the CML market that are
not yet reflected in the literature, and determine what qualitative factors may come into play in
the coming years. Interviews were conducted from October 2010 to March 2011 and included
investment analysts, basic scientific researchers, clinical hematologist/oncologists and
pharmaceutical company clinical, commercial and regulatory personnel, all with significant
experience in the CML disease space. An interview guide was used (and is included in the
appendix), but adapted slightly to the expertise of each particular interviewee.
Opinions of pathway inhibitors for cancer
The general stakeholder consensus regarding cancer pathway inhibitors (TKIs or antibodies that
target a specific cell signaling pathway) held that they represent an important scientific advance
but that research was still in relatively early stages. Certain drugs and pathways were heralded as
major advances, particularly Gleevec for CML and Herceptin for HER2-overexpressing breast
cancer. Others were promising but require further elucidation, such as EGFR inhibitors for lung
and pancreatic tumors which were shown to be highly efficacious in a fraction of the population
but much less efficacious in the remainder.
Major hurdles to pathway inhibitor development include the convoluted nature of cancer cell
signaling and the adaptability of cancer cells to overcome inhibition. Certain agents have shown
strong responses caused by inhibition of the dominant pathway, followed several months later by
incurable relapses caused by mutations elsewhere. Interviewees cited the ability of cancer cells to
mutate further downstream in the active pathway and the ability of one pathway to "feed into"
another as particularly problematic. Several specific pathways were mentioned as lucrative drug
targets in development, especially the anaplastic lymphoma kinase (ALK) pathway and HER3
(ErbB3) signaling pathway.
Interestingly, interviewees were split on the utility of narrow versus broad spectrum pathway
inhibitors. Those favoring the former cited differences between the structure and function of
related kinases, the potential for side effects from inhibiting off-target kinases and the ability to
selectively enrich patients with a certain mutation, while those favoring the latter cited the lack
of clarity into which kinases drive tumor growth ("driver" versus "passenger" mutations).
"The drugs that work are very good-the trouble is finding drugs that work" -
Commercial, large biotech
"Ten years ago, we thought targeted therapy would be the magic bullet. We since learned
that cancer cells are so smart at finding ways to overcome inhibition at single steps." -
Clinical, large biotech
"Broad-spectrum kinase inhibitors are somewhat more inelegant but have serious
activity in some diseases. " - Solid tumor oncologist
"A better idea involves combinations of highly targeted drugs. Promiscuous kinase
inhibitors have a lot of off-target effects." - Solid tumor oncologist
Opinions of pathway inhibitors for CML
Interviewees were virtually unanimous that CML represented one of the greatest areas of success
for targeted therapy. Both oncologists who treat CML and others focused on other tumor types
cited CML as a relatively well-treated cancer-the unique BCR-ABL kinase is not present in
normal cells and thus represents a natural target for treatment, the slow-growing nature of CML
translates to a lower mutation rate and rate of drug resistance and the TKIs are well tolerated.
TKIs have displaced the pre-TKI treatment regimen of interferon-a and Ara-C at all lines of
therapy, and patients with chronic phase disease may be expected to survive for many years.
However, there are unmet needs in CML treatment. Oncologists cited TKIs to treat the T3151
"gatekeeper" mutation as a major unmet need. Also highly desired is the ability to stop TKI
therapy upon achieving a complete molecular response, whether achieved through clinical data
showing that it is feasible to stop treatment, or a more sensitive measure of disease activity than
levels of BCR-ABL mRNA or positive metaphases.
It is hypothesized that there is a pool of self-renewing leukemic "stem cells" with a different
molecular profile than the majority of the tumor, and can continue to generate disease even in the
presence of optimal TKI therapy. Several pathways have been implicated in the development of
leukemic stem cells, including Wnt/-catenin and Hedgehog pathways.
"Not every cancer is CML. It's relatively simple, with less genetic abnormality than other
tumors." - Solid tumor oncologist
"The guidelines for optimal response were established for imatinib. We assume they hold
for the other two drugs but this is not firmly established." - CML oncologist
"We need a more sensitive test for mutations at the time of diagnosis." - R&D, large
pharmaceuticals
The CML market
Interviewees agreed that the market for later-line treatment could be meaningful but is small in
comparison to that for I "-line chronic disease, citing the longer duration of response and less
rapidly mutating disease. The 2"d-generation TKIs were tested in and approved for later-line
treatment, then recently moved into 1 st-line chronic disease where they can prevent mutations
occurring in the first place. Oncologists interviewed expressed enthusiasm for agents with a
broader-spectrum of action that could suppress resistant mutations from ever developing.
There was considerably less enthusiasm for the use of TKIs in later lines of therapy. Oncologists
interviewed stated that TKIs could be used to reduce tumor burden as a bridge to HSCT, but
were generally not sufficient to control the disease as monotherapy. Chemotherapeutics
appropriate to the type of blast crisis, or hydroxyurea, are commonly used to bring down the
number of tumor cells in preparation for a transplant.
"There's probably still a meaningful CML market after 1st-line use." - Research analyst
"The younger the patient is, the more years of life she has, the more dependent she will
be on a drug that more completely suppresses proliferation. Therefore, we're more likely
to use 2ndgeneration TKIs in that case." - CML oncologist
"I won't transplant a patient in blast crisis." - CML oncologist
Combination therapy
As many infectious diseases (especially HIV and tuberculosis) are treated with combination
therapy to prevent the development of resistant disease, I asked interviewees if they saw an
opportunity for combinations of therapies to treat CML. Most interviewees were pessimistic that
a combination of the three available TKIs would be beneficial to treat CML, citing overlapping
resistance spectrums and a likely antagonistic effect as all bind to the same target. On the other
hand, combinations of agents that could hit multiple targets in the same pathway for a synergistic
effect could draw physician interest.
However, interviewees were decidedly more bullish on combinations of targeted therapies for
solid tumors, citing the hypothesis that tumors with more mutations are less responsive to
targeted therapies and would require more inhibition to achieve a meaningful benefit.
"There is no rationale to combine the three TKIs that are available right now-unlike in
HIV and TB, they all hit the same target, and the additive toxicity profiles are not
encouraging." - CML oncologist
"There is limited data on the use of 2 TKIs. We don't use it much clinically." - CML
oncologist
"Cures in cancer result from combination therapy-look at the use of all-trans retinoic
acid, ara-C and anthracyclines for acute promyelocytic leukemia." - R&D, large
pharmaceuticals
"Someday, we could reach a stage where we can screen tumors for a broad array of
mutations and prescribe a cocktail of specific pathway inhibitors. It could be anywhere
from three to 10 inhibitors. However, there are some targets-like Ras, where the
mutation renders the protein unable to turn itself off, or transcription factors- that are
just not druggable." - Solid tumor oncologist
Clinical development
Interviewees generally agreed that successful development of a T3151 specific agent could be
performed with fewer patients than most CML trials, but that the rarity of the mutation could
make trial enrollment difficult. In addition, the scientific uncertainty of whether the T3151
mutation is present at baseline (albeit at lower levels than the wildtype BCR-ABL kinase) or
emerges later could make it difficult to run a combination therapy trial in I S-line disease,
relegating the trial and the approved label to patients failing a TKI and limiting the upside.
"Key opinion leaders at large academic centers are aware of T315, but a lot of
community oncologists may not be. If I had a T3151-specific agent, I'd talk about a
'broad mutational profile that covers the hardest to treat mutations' - Commercial,
large pharmaceuticals
"You could get a partial approval based on complete cytogenetic response, but the FDA
may want full survival for approval. It also may be difficult to show survival in a small
trial." - Commercial, large pharmaceuticals
Pricing and reimbursement
With respect to pricing, interviewees believe that the hypothetical drug candidate could
command a premium to other marketed TKIs, with responses ranging from 20% to 50% of the
price of the highest broad-spectrum agents. Payers are expected to continue to reimburse
efficacious agents, particularly in the U.S.
However, there are global trends towards reduced willingness to pay a premium for cancer drugs,
and a "per patient" view of costs that could impede combination therapy with expensive agents.
For example, a country that caps reimbursement for one CML patient at 50,000 Euros per year
would preclude the use of combination therapy.
"For example, the problem isn't paying for Herceptin, but people who aren't HER2-
positive getting the drug." - Payer
"In the case of [Drug A], they knew the data wasn't so great and went for last-line
therapy at a 10-15% premium. In rare cases you can command a 50% premium." -
Commercial, large pharmaceuticals
Discussion and conclusion
Hypothetical candidate is unlikely to be developed
In this instance, it is doubtful that the hypothetical drug candidate for CML will be purposefully
developed. The existence of a small and relatively well-treated CML population and the rarity of
this particular mutation will severely limit the size of the market and thus the expected NPV and
the expedited development process will not adequately compensate for this. There is the
additional factor of opportunity cost: a company faced with this question may have several
projects more deserving of manpower and effort.
At the start of this work, I thought that a genotype-directed therapy for CML could be a viable
clinical development option. Many targeted cancer therapy development programs successfully
conceded a large share of the patient population in exchange for premium pricing, expedited
development and more robust efficacy. The particular case of a narrow-spectrum T315I CML
drug illustrates the limits of this approach, since the mutation is too rare to support a market on
its own. It is more likely that this combination therapy approach (T3151 BCR-ABL kinase
inhibitor in combination with a marketed 1 "-line agent) would be used only to salvage a drug
candidate that had failed in a broader treatment population.
On the other hand, CML is an atypical cancer-it is rare and well-treated-and so genotype-
directed therapies may yet prove profitable in other indications. A more prevalent cancer or
specific resistant genotype could represent a commercially viable market, especially if it
represents a major treatment advance (in efficacy or safety) over its comparators and patients
will stay on drug for a long period of time. As more pathway inhibitors are approved, it is likely
that they will be associated with specific resistance mutations and that some of these will
represent clinically and commercially viable drug targets.
Broader applications and extensions of this work
The goal of the model was to systematize available data on drug sales, efficacy and tolerability
profiles, and disease biology and epidemiology to come to a relatively rigorous view of the CML
market. While I chose CML for several reasons including the availability of data, clearly
delineated disease phases, and demonstrated commercial interest, "state-transition" models of the
sort that I created could be used to describe patient progress and outcomes for many chronic
87diseases and have been used for such for some time
Further extensions of the model work could include:
" Testing implications of how and when resistance mutations become apparent.
Improved mutation detection and the presence of resistance mutation at baseline would
permit early treatment to suppress all clones of the disease, improve prognosis, and allow
use of the hypothetical candidate in the first line. On the other hand, acquisition of
mutations during treatment, or leukemic stem cells that resist TKI therapy would not
open up the I s-line market.
" Genotype-directed therapy as salvage. I treated the hypothetical candidate as a drug
candidate tailored to a resistant genotype. In this scenario, if the hypothetical candidate
would be geared towards 14s-line disease but rather than "succeed or fail" in clinical trials,
there could be a third probability that the drug fail in the broader trial population but
succeed in in a select genotype (as determined by post hoc analysis and be tested only in
this select population going forward), the drug's value proposition could change
significantly.
e Market effect of a curative therapy. Much of the value of the CML market results from
patients being on TKI therapy for the rest of their lives. If one of the three marketed CML
TKIs, or a new agent, could be stopped upon achieving a given efficacy threshold, the
market dynamics could change dramatically. The curative therapy could justify greater
pricing but sharply curtail duration of therapy.
* Simulation. Ability to test for mean and variance of NPV (rather than just an expected
NPV) will affect the company's ability to value and "de-risk" the development program.
e Other tumor types. Any tumor for which 1) 14t-line targeted therapy delays disease
progression for a significant interval and is unlikely to be displaced by the hypothetical
agent, 2) resistance is associated with a specific, druggable mutation and 3) long-term
data is available could be addressed with a similar model.
The model could be easily applied to other types of cancer, with modifications. Most
malignancies would lack the equivalent of a "chronic phase" and be diagnosed only after a
significant tumor burden and clonal evolution develops, and patients would start at an
"accelerated phase." Tumors with an especially poor prognosis such as advanced non-small-cell
lung cancer or pancreatic cancer will show similar survival rates to a CML blast crisis. Similarly,
adjuvant treatment could be modeled by an "adjuvant" phase and a risk of relapse or diagnosis of
metastasis at a given time point.
Conclusion
The first TKI for CML, Gleevec, not only revolutionized the CML treatment paradigm, but also
conjured widespread hope that cancer could be cured or halted with a pill". One interviewee
specifically cited Gleevec as one of the foremost examples of academic scientists and
pharmaceutical companies collaborating effectively (as contrasted with expensive agents that are
hailed as an advance but only confer small therapeutic benefit). This work both advanced the
understanding of cancer and transformed the lives of a small but underserved patient population.
While better understanding of cancer biology and signaling has tempered the expectation that all
cancers could be managed with a single pill, targeted therapies remain one of the most important
areas in cancer research.
Just as Gleevec transformed CML from an inexorable disease to a chronic, manageable
condition, new markets for resistant disease have similarly transformed CML with certain
Gleevec-resistant mutations into a chronic disease. This process of "covering" specific mutations
can be expected to continue as long as a reasonable profit may be made in doing so-at some
point, the number of patients with important unaddressed BCR-ABL kinase mutations in CML
may be too few to proceed with further development. The hypothetical drug candidate tested in
the model is one such example.
It is possible that several such markets may evolve at once as inhibitors of other pathways
become commercially available for solid tumors, are used simultaneously, and resistance
mutations start to develop. This raises the question of how signaling molecules and pathways
interact with one another, the exploration of which is still in early stages. As our understanding
of these interactions evolves, the market is likely to change in ways that are difficult to
anticipate. This will require increasing collaboration between clinical oncologists, basic scientific
researchers, industry and regulators to advance the state of cancer treatment.
Appendix
Interview guides
Investment analysts
1. What stocks in the oncology treatment space do you cover and why did you choose to cover
them? How do you (and your clients) view oncology companies focused on tyrosine kinase
inhibitors? How has the level of interest changed in recent years?
2. Walk me through your model of CML, and specifically how the drug for refractory/T3151
disease fits in. If possible, how do you view the potential use of this drug in chronic phase,
accelerated phase, blast crisis, and Ph+ AML? What efficacy (major cytogenetic response for
chronic phase, complete hematologic response for later phases)/safety/dosing do you assume in
the resistant setting, and how sensitive is your model to each?
3. What could move such a drug into earlier lines of therapy (e.g. ahead of
Gleevec/Tasigna/Sprycel)? How costly would such a study be?
4. What other cancer indications could such an agent be useful in? How do you look at these
markets?
5. How could you see these agents being used in combination with each other, or other targeted
agents?
6. Do you believe it will be possible to make cancer a chronic disease that could be managed
with single or combination targeted therapies alone? What are the necessary conditions for this to
happen?
Commercial managers
1. In your opinion, have signaling/pathway inhibitors lived up to their promise in treating cancer?
Why or why not? How has your opinion of the overall market for these agents (by small
molecule, antibody, other) changed over the last 3-5 years?
2. What do you see as the benefits to broad-spectrum multi-pathway inhibition versus more
targeted inhibition? How does mechanism of action play into your marketing strategy,
particularly in your thoughts on the matter before Phase III data is announced?
3. How do you think about the market opportunity for therapies directed at tumors of a specific
genotype in terms of patients, line of treatment, duration, pricing, and resistance mutation
profile? Assuming similar efficacy/safety/dosing to currently marketed therapies for a given
indication and line (or if none such as for T3151 CML, to first line therapy).
4. What are the boundary conditions for #3? (i.e. at what point does the market become too
small, the testing too onerous, etc)
5. How would you commercialize a drug for a specific tumor genotype differently from an "all
comers" cancer drug? How would a requirement for Bcr-Abl sequencing at regular intervals
affect commercialization?
6. What can you tell me about your line extension strategy? How can you see this drug being
used as sequential or combination therapy, and are there trials underway (or in process, planning,
etc) to achieve this end?
7. Do you believe it will be possible to make cancer a chronic disease that could be managed
with single or combination targeted therapies alone (with genotyping/karyotyping/other
molecular test to check for resistances, etc)? What are the necessary conditions for this to
happen?
Clinical managers
1. In your opinion, have signaling/pathway inhibitors lived up to their promise in treating cancer?
Why or why not? How has your opinion of the overall market for these agents (by small
molecule, antibody, other) changed over the last 3-5 years?
2. What are the particular challenges of designing a clinical trial for a specific mutant genotype
of tumor (e.g. T3151 in CML)? How would this influence adaptive design, comparator arms, etc?
3. Do you believe it will be possible to make cancer a chronic disease that could be managed
with single or combination targeted therapies alone (with genotyping, karyotyping, or other
molecular test to check for resistances)? What are the necessary conditions for this to happen?
4. How would you design a trial meant to achieve this outcome differently? How would the
timing of such a trial change? What is the regulatory environment towards such a trial?
5. How would the cost or size of a trial differ from published figures for oncology? What would
be the impact of having to develop a diagnostic test?
Researchers
1. What is your opinion on the theory of oncogene addiction? Do you think that it is broadly
applicable to many tumor types or not?
2. In your opinion, have signaling/pathway inhibitors lived up to their promise in treating cancer?
Why or why not?
3. What do you see as the benefits to broad-spectrum pathway inhibition (similar to Sutent,
Nexavar) versus more targeted pathway inhibition?
4. What phase of disease do you believe is best indicative of "cancer" as a whole (in terms of life
expectancy, degree of genetic/karyotypic aberration, etc)?
5. How important is resistance spectrum in designing a new therapy? When does a specific
mutant become problematic enough to warrant more research towards discovering a treatment?
6. What would be the considerations in designing a combination targeted therapy regimen for
cancer? Optimally, what kind of effects could this have? What more do we need to understand
about cancer biology to bring this about?
7. What pathways do you see as the most promising or potentially promising? If nothing has
been developed to treat it, why is that the case?
8. What do you believe is the most promising general area in early stage cancer research? How
close is this to yielding viable clinical/therapeutic options?
9. What are the limitations of current methodologies? What up-and-coming methodologies hold
the greatest promise?
Oncologists
1. How should we think about the CML treatment paradigm? How much controversy surrounds
the use of (Drug A) in a given setting?
2. What do you consider an adequate response to (Drug A) at a given timepoint?
3. In what percent of patients do you use (Drug A) at a given line of therapy? What other
treatments do you use (including HSCT or off-label agents)?
4. What do you use to treat T3151 CML or other highly refractory or resistant patients?
5. What sorts of treatments would you like to have available? Do you feel like current treatments
are adequate for the majority of patients?
6. What are your opinions on drugs that specifically target resistant populations (such as T3151
mutant tumors)? What efficacy/safety/dosing/resistance profile would you need to see?
7. Have you ever used combination therapy of BCR-ABL inhibitors? If so, what was your
rationale? If not, why not? Is this a worthwhile approach to prevent escape mutants, or does this
remove an option downstream? How would a genotype-specific therapy in general fit into this
framework?
8. CML and other hematological malignancies often see some of the earliest breakthroughs in
therapy-how representative is CML of other malignancies?
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